CC 401
Alternative Names: CC-401; JNK-401Latest Information Update: 04 Dec 2019
At a glance
- Originator Celgene Corporation
- Class Small molecules
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cancer; Inflammation
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 31 Oct 2005 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
- 12 Nov 2003 Phase-I clinical trials in Cancer in USA (IV)